DIPHENYLGUANIDINE: 14 Adverse Event Reports & Safety Profile
Sharpen Your Memory & Focus Naturally
NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.
14
Total FAERS Reports
6 (42.9%)
Deaths Reported
12
Hospitalizations
14
As Primary/Secondary Suspect
4
Life-Threatening
First Report: 20191029 · Latest Report: 20201001
What Are the Most Common DIPHENYLGUANIDINE Side Effects?
#1 Most Reported
Pulmonary pain
14 reports (100.0%)
#2 Most Reported
Lower respiratory tract infection
14 reports (100.0%)
#3 Most Reported
Arthropathy
14 reports (100.0%)
All DIPHENYLGUANIDINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Arthropathy | 14 | 100.0% | 6 | 12 |
| Lower respiratory tract infection | 14 | 100.0% | 6 | 12 |
| Pulmonary pain | 14 | 100.0% | 6 | 12 |
| Product dose omission issue | 13 | 92.9% | 6 | 11 |
| Abdominal discomfort | 12 | 85.7% | 6 | 10 |
| Knee arthroplasty | 12 | 85.7% | 6 | 10 |
| Rash | 12 | 85.7% | 6 | 10 |
| Drug abuse | 11 | 78.6% | 5 | 10 |
| Intentional product misuse | 11 | 78.6% | 5 | 10 |
| Off label use | 11 | 78.6% | 6 | 9 |
| Overdose | 10 | 71.4% | 5 | 9 |
| Amyloid arthropathy | 6 | 42.9% | 0 | 6 |
| Condition aggravated | 6 | 42.9% | 6 | 4 |
| Covid-19 | 6 | 42.9% | 6 | 4 |
| Inflammation | 6 | 42.9% | 6 | 4 |
| Lung neoplasm malignant | 6 | 42.9% | 6 | 4 |
| Obesity | 6 | 42.9% | 0 | 6 |
| Radiation inflammation | 6 | 42.9% | 6 | 4 |
| Schizophrenia | 6 | 42.9% | 6 | 4 |
Who Reports DIPHENYLGUANIDINE Side Effects? Age & Gender Data
Gender: 63.6% female, 36.4% male. Average age: 63.6 years. Most reports from: GB. View detailed demographics →
Is DIPHENYLGUANIDINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2019 | 1 | 0 | 1 |
| 2020 | 10 | 6 | 8 |
What Is DIPHENYLGUANIDINE Used For?
| Indication | Reports |
|---|---|
| Depression | 11 |
| Abdominal discomfort | 9 |
| Product used for unknown indication | 6 |
Official FDA Label for DIPHENYLGUANIDINE
Official prescribing information from the FDA-approved drug label.